ArisGlobal, a leading provider of solutions to the life sciences industry, has announced that agDisclosure, its clinical trial disclosure solution, now supports Version 10 of the European Medicines Agencys EudraCT database
ArisGlobal, a provider of solutions to the life sciences industry, has announced that agDisclosure, its clinical trial disclosure solution, now supports Version 10 of the European Medicines Agency’s EudraCT database (European Union Drug Regulating Authorities Clinical Trials). EudraCT Version 10 makes the reporting of summary results mandatory to EudraCT, including those for legacy studies by July 2015 or July 2016, depending on the age of the trial. agDisclosure now supports reporting of results to both ClinicalTrials.gov and EudraCT, allowing customers to use ClinicalTrials.gov data and transform it to EudraCT data. agDisclosure supports the complete trial disclosure process – from gathering required data, reviews by stakeholders, conducting checks against registry-specific validation rules, to generating XML files for upload and automatic submission. Read the full release here.
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
February 6th 2025In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.